Adjusted EPS loss of $(0.25) missed the consensus of $(0.20).
Adjusted gross margin contracted 1,030 basis points Y/Y to 63.4%, and the adjusted gross profit nearly halved to $45.3 million.
Total operating expenses decreased 11% to $70.2 million. The operating loss for the quarter was $(26) million versus an income of $7.2 million a year ago.
Adjusted EBITDA loss was $(15.4) million with an adjusted EBITDA loss margin of (21.5)%.
Cognyte held $61.2 million in cash and equivalents as of October 31, 2022. Net cash used in operating activities for the nine months totaled $(46.14) million.
Cognyte’s CEO Elad Sharon, said, “In the third quarter, we continued to win large orders and our backlog increased sequentially. At the same time, slow backlog conversion drove a sequential revenue decline. We expect to resume sequential revenue growth in the fourth quarter of fiscal year 2023, which we believe will be a turning point.”
Outlook: Cognyte sees Q4 adjusted sales of $65 million – $74 million versus the Street view of $84.31 million.
The company expects FY24 revenue growth of 5%.
The company targets breakeven cash flow from operations in the current quarter and for the full year ending January 31, 2024.
Price Action: CGNT shares are trading higher by 15.32% at $2.71 in premarket on the last check Tuesday.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
